Serum CA125, CA199, CEA, CA724, and AFP for diagnosis and prognosis prediction in patients with intrahepatic cholangiocarcinoma

Objective:Intrahepatic cholangiocarcinoma(ICC)is a malignancy that involves difficulties in early diagnosis and has extremely poor prognosis.This study aimed to evaluate serum carbohydrate antigen 125(CA125),serum carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),carbohydrate antigen 724(CA724)and alpha-fetoprotein(AFP)as biomarkers for diagnosis and prognosis of ICC patients.

Value of CA19-9, CA125 and CEA combined magnetic resonance imaging in the diagnosis of pancreatic cancer

Objective:To study the value of CA19-9, CA125 and CEA combined magnetic resonance imaging (MRI) in the diagnosis of pancreatic cancer, and to provide a reference for clinical diagnosis and treatment.Methods:A total of 110 cases of pancreatic cancer admitted to our hospital from November 2015 to November 2017 were selected as the observation group, and another 80 normal pancreas organizers who participated in the physical examination in the same period were selected as the control group. The change of magnetic resonance scanning parameters and serum CA19-9, CA125 and CEA detection were compared between the two groups of subjects at the same time, contrast scan and serum magnetic resonance detection of CA19-9, CA125 and CEA positive rate, and to evaluate the four alone and in combination with the diagnosis of pancreatic cancer specificity, sensitivity, negative predictive value and positive predictive value.Results:The T1WI of the observation group was low or slightly low signal, T2WI was slightly high signal, and the tumor of fat suppression sequence was low signal, which was in line with the typical characteristics of pancreatic cancer. The serum levels of CA19-9, CA125 and CEA in the observation group were significantly higher than those in the control group, and the difference was statistically significant. Compared with the two groups, the positive rates of MRI and serum CA19-9, CA125 and CEA in the observation group were higher than those in the control group, and the difference was statistically significant. The sensitivity and accuracy of MRI scan combined with three serological markers were higher than those of single detection. The specificity was between four.Conclusion: CA19-9, CA125 and CEA combined magnetic resonance imaging (MRI) have good sensitivity and accuracy in diagnosis of pancreatic cancer, but their specificity is common, which should be used for reference.

Effect of rabdosia rubescens combined with new assistant chemotherapy on serum CA199, CEA, CA15-3 and T lymphocyte subsets in patients with breast cancer

Objective:To study the effects of Rabdosia rubescens combined with neoadjuvant chemotherapy on serum CA199, CEA, CA15-3 levels and T lymphocyte subsets in patients with breast cancer.Methods: A total of 70 patients with breast cancer in our hospital were enrolled as the subjects of this study. The subjects were divided into control group (n=35) and treatment group (n=35) randomly. Patients in the control group were treated with new assistant chemotherapy, while those who were in the treatment group were treated with rabdosia rubescens combined with new assistant chemotherapy. The two groups of patients were treated for 3 periods. The serum CA199, CEA, CA15-3 levels and peripheral blood CD4+, CD8+, CD4+/CD8+ cells of the two groups before and after treatment were compared.Results:There were no significantly differences among the serum CA199, CEA, CA15-3 levels and peripheral blood CD4+, CD8+, CD4+/CD8+ cells of the two groups before treatment. The serum CA199, CEA and CA15-3 levels of the two groups after treatment were significantly lower than those before treatment, besides, the serum CA199, CEA and CA15-3 levels of the treatment group were significantly lower than those of the control group. The peripheral blood CD4+, CD4+/CD8+ cells of the control group after treatment were significantly lower than before treatment, and the peripheral blood CD4+, CD4+/CD8+ cells of the treatment group after treatment were significantly higher than those of the control group.Conclusion:Rabdosia rubescens combined with new assistant chemotherapycan can significantly reduce the serum CA199, CEA and CA15-3 levels, and improve peripheral blood CD4+, CD8+, CD4+/CD8+ levels of patients with breast cancer. It is worthy of clinical application.

Clinical efficacy and effect on serum HE4, SMRP, CA125, CA199, B7-H4, TPS of carboplatin combined with paclitaxel for patients with ovarian cancer

Objective:To study the clinical efficacy and effect on serum HE4, SMRP, CA125, CA199, B7-H4, TPS of carboplatin combined with paclitaxel for patients with ovarian cancer.Methods:A total of 80 patients with ovarian cancer in our hospital from December 2014 to December 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with carboplatin;the treatment group was treated with carboplatin combined with paclitaxel. 21 d for a period of treatment and the two groups were treated for 2 periods. The serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups before and after treatment was compared. Results:There were no significantly differences of the serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups before treatment. The serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly lower than that of the control group.Conclusion: Carboplatin combined with paclitaxe for patients with ovarian cancer can significantly reduce the serum HE4, SMRP, CA125, CA199, B7-H4, TPS levels;can be used for the prognosis of patients with ovarian cancer after treatment.

联合检测CA125 CA199和CEA对卵巢癌诊断价值的Meta分析

目的:评价联合检测血清CA125、CA199、CEA在卵巢癌诊断中的价值。方法:计算机检索Pubmed、CBMdisc、CNKI、维普等数据库,收集关于卵巢癌诊断中联合检测CA125、CA199、CEA的文献。采用Meta-DiSc 14.0、Stata10.0进行Meta分析。结果:按照统一的纳入标准和排除标准获得12篇文献。结果显示在卵巢癌诊断中,联合检测CA 125、CA199、CEA的灵敏度(SE)、特异度(SP)、诊断比值比(DOR)、SROC曲线下面积(AUC)、Q指数分别为0.90(0.88～0.93)、0.83(0.80～0.86)、39.75(22.58～69.97)、0.953、0.895。单独检测CA125的SE、SP、DOR、AUC、Q指数分别为0.73(0.69～0.77)、0.88(0.86～0.91)、17.45(9.95～30.48)、0.804、0.739。两种检测方式的诊断效能比较差异有统计学意义(Z=4.859,P<0.05)。结论:卵巢癌的临床辅助诊断中,与单独检测CA125比较,联合检测CA125、CA199、CEA的判别能力较强、准确率较高,可提高诊断效能。

Value and significance of tumor markers as CEA,CA125,SCC-Ag,CA199 and CYFRA21-1 in the diagnosis of cervical cancer

Objective: To investigate the value and significance of serum CEA, CA125, SCC-Ag, CA199 and CYFRA21-1 in the diagnosis of cervical cancer by comparing the detection of five serum markers. Methods: A total of 108 cases were divided into three groups, including 60 cervical cancerpatients and 20 cervical intraepithelial neoplasiain patients treated in our hospital from September 2015 to September 2016 and 28 healthy women. Radioimmunoassay was used to detect and compare the serum levels of CA125, CA199, CYFRA21-1 and ELISA method was used to detect and compare the serum levels of SCC-Ag, CEA. Results: (1) There was no statistically significant difference in the serum CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels between CIN group and control group. The serums CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels of cervical cancer patients were significantly higher than the other two groups. The differences were statistically significant. (2)There were statistically significant differences in the serum CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels between different cervical pathological type groups.The serum CA125, CA199, CEA levels of cervical glandular cancer patients were significantly higher than the other two groups. The differences were statistically significant. The serum SCC-Ag, CYFRA21-1 levels of cervical squamous cancer patients were significantly higher than the other two groups. The differences were statistically significant. Conclusion: The serums CEA, CA125, SCC-Ag, CA199, CYFRA21-1 levels of cervical cancer patients were significantly higher than cervical intraepithelial neoplasiain patients and healthy women. The serum CA125, CA199, CEA levels of cervical glandular cancer patients were significantly higher and the serum SCC-Ag, CYFRA21-1 levels of cervical squamous cancer patients were significantly higher. The five tumor markers can be used in diagnosis of cervical cancer and they are also worthy in distinguishing cervical pathological types.

血清CEACA199 CA125及血浆M2-PK联合检测在胃癌诊断中的临床研究

目的探讨血清癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原125(CA125)及血浆M2-丙酮酸激酶(M2-PK)联合检测在胃癌诊断中的临床应用价值。方法选择2017年6月—2017年10月我院收治的良性胃病患者30例为A组,选择同期在我院进行体检的健康志愿者30例为B组,30例胃癌患者为C组,分别采用酶联免疫吸附法(ELISA)检测3组M2-PK水平,采用电化学发光法(ECLIA)检测3组CEA、CA199及CA125水平,比较3组相关指标检测结果。结果 C组患者M2-PK、CEA、CA199、CA125水平均明显高于A组与B组,差异具有统计学意义(P<0.05);C组患者M2-PK、CEA、CA199、CA125阳性检出率明显高于A组与B组,差异具有统计学意义(P<0.05);四者联合检测的灵敏度明显高于单独检测,且特异度明显高于CEA、CA125单独检测,差异具有统计学意义(P<0.05)。结论血清M2-PK、CEA、CA199、CA125水平检测对临床诊断胃癌具有较高的辅助价值,且四者联合检测能显著提高诊断的特异性和敏感性。

TVCDS联合血清CA125、CEA、HE4、CA199水平检测在早期子宫内膜癌诊断中的应用价值

观察多指标联合检测早期子宫内膜癌价值。方法 时间2022年,对象是子宫内膜癌患者(早期子宫内膜癌患者组)、健康人员(健康体检组),样本量60例,研究TVCDS检查资料、血清肿瘤标志物资料。对比结果。结果 早期子宫内膜癌患者组,与健康体检组对比,检测值[CA125水平:(218.49±24.18)U/mL对比(8.08±2.33)U/mL;血清CEA水平:(26.19±7.15)ug/L对比(2.23±0.14)ug/L;血清HE4水平:(278.59±19.15)pmol/L对比(39.16±4.33)pmol/L;血清CA199水平:(291.37±25.37)U/mL对比(7.36±2.06)U/mL],均更高(p<0.05)。经TVCDS+血清CA125+血清CEA+血清HE4+血清CA199水平检测,对比TVCDS检查,早期子宫内膜癌的临床确诊率[96.66%(58/60)对比83.33%(50/60)]更高(p<0.05)。经TVCDS检查+血清肿瘤标志物检测,早期子宫内膜癌的临床漏诊率,对比TVCDS检查[1.67%(1/60)对比13.33%(8/60)]更低(p<0.05)。经TVCDS检查+血清肿瘤标志物检测,早期子宫内膜癌误诊率,对比TVCDS检查[1.67%(1/60)对比3.33%(2/60)]更低,但无差异性(p>0.05)。经TVCDS检查+血清肿瘤标志物检测,早期子宫内膜癌的临床确诊率,对比临床手术病理检测[96.66%(58/60)对比100.00%(60/60)],无差异性(p>0.05)。结论 对早期子宫内膜癌患者,行TVCDS+血清CA125+血清CEA+血清HE4+血清CA199水平检测,检测价值更高。

血清CA125,CEA,CA199与胃癌病理特征的相关性

目的 探讨胃癌患者在血清糖类抗原125(CA125)、癌胚抗炎(CEA)、糖类抗原199(CA199)的表达情况,分析血清肿瘤标志物同临床病理特征关系。方法 纳入2019年1月~2023年3月收治的胃癌者118例,根据病理结果,针对进展期胃癌纳入观察组82例,早期胃癌纳入对照组36例。测定患者血清CA125、CEA、CA199水平,针对不同临床病理特征(性别、年龄、肿瘤类型)的血清指标进行分析,针对单项指标与联合指标对胃癌阳性结果比较。结果 观察组血清CA125、CEA、CA199水平高于对照组(P<0.05);不同年龄、肿瘤类型患者,测定CA125、CEA、CA199水平(P<0.05);针对胃癌检出阳性率,采取CA125+CEA+CA199联合指标阳性率为68.64%。结论 胃癌者血清肿瘤标志物水平均高于正常值,其中进展期胃癌指标水平高于早期胃癌。经指标联合测定辅助病变判定价值突出,值得推广。

血清CA125、CA199、AFP、CEA联合检测对卵巢癌的诊断价值

目的探讨血清CA125、CA199、AFP、CEA联合检测对卵巢癌的诊断价值。方法选取40例卵巢癌患者纳入恶性组,48例卵巢良性肿瘤患者纳入良性组,40例健康者纳入对照组。比较三组的血清CA125、CA199、AFP、CEA水平,绘制ROC曲线评价CA125、CA199、AFP、CEA单独及联合检测对卵巢癌的诊断效能。结果恶性组的血清CA125、CA199、AFP和CEA水平均高于良性组及对照组,良性组的上述指标水平均高于对照组(P<0.05)。ROC曲线显示,联合检测对卵巢癌的诊断效能优于各指标单独检测。结论血清CA125、CA199、AFP、CEA联合检测诊断卵巢癌的价值较高,值得临床推广应用。

CEA与CA199及CA125等多项肿瘤标志物联合病理检测在胃癌诊断中的效果观察

观察分析在胃癌诊断中应用血清CEA与CA199及CA125等多项肿瘤标志物联合病理检测的临床价值。方法 本次研究共纳入59例患者,其中包括30例胃癌患者,设置为观察组;29例良性胃病患者,设置为对照组,病例来源均为我院收住院患者,收住院时间均在2021年3月-2022月3月之间。2组患者收住院以后,均检测血清肿瘤标志物,包含癌胚抗原(CEA)、糖类抗原-199(CA199)、糖类抗原-125(CA125)与糖类抗原-724(CA724)4项,观察分析在胃癌诊断中应用血清肿瘤标志物联合检测的价值,评估对比肿瘤分期为Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期胃癌患者在血清CEA、CA125、CA199与CA724水平中存在的差异。结果 观察组胃癌患者与对照组良性胃病患者血清4项肿瘤标志物含量对比,观察组在两组中显然更高,差异有统计学意义(P<0.05)。观察组中肿瘤分期为Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期患者血4项肿瘤标志物含量对比,肿瘤分期为Ⅲ期、Ⅳ期患者含量显然高于Ⅰ期、Ⅱ期患者,差异有统计学意义(P<0.05)。结论 CEA与CA199及CA125等多项肿瘤标志物联合病理检测在胃癌诊断中具有较高应用价值,尤其是中晚期胃癌;同时对预测评估胃癌患者病情严重程度具有一定的临床意义。

CA125、CA199与CEA联合检测对卵巢癌的诊断价值

目的探讨糖类抗原125(carbohydrate antigen125, CA125)、糖类抗原199(carbohydrate antigen199,CA199)与癌胚抗原(carcinoembryonic antigen, CEA)联合检测对诊断卵巢癌的价值。方法 选取2019年12月-2023年4月高邮市中医医院收治的卵巢癌患者41例为观察组,健康体检者41例为对照组,比较两组CA125、CA199与CEA水平;评估3项指标单独与联合检测对诊断卵巢癌的价值;将卵巢癌患者分为临床分期Ⅰ~Ⅱ期组,Ⅲ~Ⅳ期组,比较两亚组肿瘤标志物检测水平。结果 观察组CA125、CA199、CEA均高于对照组,差异有统计学意义(P<0.05)。联合诊断准确率、灵敏度均高于CA125、CA199、CEA单独检测,差异有统计学意义(P<0.05)。联合诊断特异度与CA125、CA199、CEA单独检测比较,差异无统计学意义(P>0.05)。Ⅰ~Ⅱ期组CA125(305.42±48.70)U/mL、CA199(58.44±5.86)U/mL、CEA(12.85±3.72)ng/mL,均低于Ⅲ~Ⅳ期组,差异有统计学意义(t=5.567、16.438、4.501,P<0.05)。结论 卵巢癌患者CA125、CA199与CEA指标明显异常,指标联合检测对卵巢癌的诊断效能高,且Ⅲ~Ⅳ期患者CA125、CA199与CEA水平较Ⅰ~Ⅱ期更高。

CEA、CA125、CA199及AFP联合检测对卵巢癌的诊断价值

目的 评价卵巢癌诊断中进行抗原199(carbohydrate antigen199,CA199)、糖链抗原125(carbohydrate antigen125,CA125)、癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetoprotein,AFP)联合检测的价值,为卵巢癌疾病诊断工作提供参考,以尽早干预、促进患者预后。方法 选择我院2018年8月至2019年10月期间收治的卵巢癌、卵巢良性肿瘤患者,各选取80例,作为观察1组与观察2组。另外,选择同期80名健康体检者,作为对照组。经医院伦理委员会审核批准,参与者知情同意配合,观察1组、观察2组与对照组受检人群均进行CEA、CA125、CA199、AFP联合检测,对比3组受检人群的相应检测结果以及联合检测、单项检测阳性率情况。结果 3组受检人员组间CEA、CA125、CA199、AFP检测结果比较,观察1组卵巢癌患者的各项指标检测结果 CA199(78.30±33.20)U/m L、CA125(82.70±45.50)U/m L、CEA(12.25±5.05)μg/L、AFP(37.60±15.05)μg/L均明显高于观察2组和对照组,P<0.05。另外,观察1组卵巢癌患者联合检测阳性率明显高于CEA、CA125、CA199、AFP单一检测,P<0.05。结论 CA199、CA125、CEA、AFP联合检测敏感度较高,能够提高卵巢癌疾病诊断准确率,做到早发现、早治疗,从而提供卵巢癌疾病患者的预后,提供患者的生活与生存质量。

CEA、CA125、CA199及AFP联合检测在消化系统肿瘤诊断中的临床价值

目的:探析消化系统肿瘤采取癌胚抗原(CEA)、糖类抗原(CA125)、糖类抗原(CA199)及甲胎蛋白(AFP)联合检测的诊断价值。方法:抽取2019年1月~2022年1月扬州友好医院收治的200例消化系统疾病患者作为研究对象,经手术病理确诊分成恶性组(n=100)、良性组(n=100),另选择同一时期接受体检的100例健康人群作为对照组,所有患者均完成CEA、CA125、CA199及AFP检测,对比3组CEA、CA125、CA199、AFP等含量,同时记录恶性肿瘤不同分期的CEA、CA125、CA199、AFP数值,对比恶性肿瘤CEA、CA125、CA199、AFP及联合诊断的阳性符合率。结果:与良性组、对照组相比,恶性组CEA、CA125、CA199、AFP等血清含量明显较高,差异有统计学意义(P<0.05);消化道肿瘤分期越高,其CEA、CA125、CA199及AFP含量越高,差异有统计学意义(P<0.05);CEA用于结肠癌、CA125用于胃癌、CA199用于胰腺癌、AFP在肝癌的阳性符合率最高,差异有统计学意义(P<0.05);相对于单一诊断来说,4项联合的阳性符合率较高,差异有统计学意义(P<0.05)。结论:CEA、CA125、CA199及AFP联合用于消化恶性肿瘤的诊断中具有较为理想的准确率,能为临床制定针对性的治疗方案提供依据。

肝癌与肝硬化患者的血清CA125、CEA、AFP和CA199水平比较

目的:比较肝癌与肝硬化患者的血清癌胚抗原(CA125)、癌胚抗原(CEA)、甲胎蛋白(AFP)和癌抗原(CA199)水平。方法:选取2020年1月至2022年1月本院收治的70例原发性肝癌患者为观察组,70例健康体检者作为健康对照组,70例肝硬化患者为疾病对照组。检测观察组、健康对照组和疾病对照组的血清CA125、CEA、AFP和CA199水平。结果:观察组肝癌患者的血清CA125、CEA、AFP和CA199水平明显高于疾病对照组患者和健康对照组(P<0.05),且疾病对照组患者的血清CA125、CEA、AFP和CA199水平明显高于健康对照组(P<0.05)。结论:肝癌患者的血清CA125、CEA、AFP和CA199水平明显高于肝硬化患者。

检测胸水中CEA、CA125、CA153及CA199对肺癌的诊断价值

目的 探讨检测胸水中癌胚抗原 (CEA)、癌抗原 12 5 (CA12 5 )、癌抗原 15 3 (CA15 3 )及癌抗原 199(CA199)在肺癌诊断中的应用价值。方法 采用化学发光法对 5 2例肺癌患者的胸水、血清及 5 0例非肺癌患者的胸水进行了免疫蛋白定量分析。结果 肺癌组胸水内 4项标志物水平均明显高于非肺癌组水平 (P <0 .0 1或P <0 .0 5 ) ;肺癌组胸水中 4项标志物水平明显高于血清中水平 (P <0 .0 1或P <0 .0 5 ) ;CEA与CA199联合检测其敏感性和特异性高达 96.2 %和 96.0 %。结论 检测胸水中CEA、CA12 5、CA15 3及CA199对肺癌的诊断具有重要的临床意义 。

CA125、CA199、CEA联合检测在卵巢癌诊断中的应用

目的探讨血清CA125、CA199、CEA联合检测在卵巢癌诊断中的临床价值。方法采用化学发光微粒子免疫分析技术(CMIA)测定72例卵巢癌患者、51例妇科良性疾病患者和60例健康女性血清中CA125、CA199、CEA的含量。结果卵巢癌组的CA125、CA199、CEA的水平和阳性率显著高于健康对照组(P<0.05);卵巢癌组的CA125、CA199的水平和阳性率显著高于妇科良性疾病组(P<0.05);3项肿瘤标志物中,CA125阳性率最高(75%);CA125、CA199、CEA联合检测的敏感性为88.89%,特异性为88.29%,阳性预测值为83.12%,阴性预测值为92.45%;与CA125单项指标相比较,联合检测的特异性略有下降,其余指标均高于单项检测;Ⅰ期、Ⅱ期卵巢癌患者CA125单项检测的阳性率(Ⅰ期:27.27%、Ⅱ期:46.67%)明显低于Ⅲ期、Ⅳ期患者(Ⅲ期:94.12%、Ⅳ期:100%),CA125、CA199、CEA联合检测明显提高了Ⅰ期、Ⅱ期卵巢癌患者诊断的阳性率(Ⅰ期:63.64%、Ⅱ期:80%)。结论 CA125、CA199和CEA 3项联合检测是检查卵巢癌较为理想的标志物组合。

CEA、CA125、SCC-Ag、CA199及CYFRA21-1等肿瘤标志物在宫颈癌中诊断的价值和意义

目的:通过对研究对象五种肿瘤标志物的检测比较,探讨CEA、CA125、SCC-Ag、CA199及CYFRA21-1等不同肿瘤标志物在宫颈癌中诊断的价值和意义。方法:对108例研究对象进行分组,按照疾病类型分为三组,其中包括在我院进行诊治的宫颈癌患者60名,宫颈上皮内瘤变(CIN)患者20名,同期门诊体检健康妇女28名。用放射免疫分析法检测三组研究对象的CA125、CA199和CYFRA21-1水平;用ELISA(酶联免疫吸附法)检测血清SCC-Ag、CEA水平,并进行对比。结果:(1)CIN组与健康对照组CA125、CA199、CYFRA21-1、SCC-Ag、CEA水平之间无显著性差异(P>0.05);宫颈癌组CA125、CA199、CYFRA21-1、SCC-Ag、CEA水平均明显高于健康对照组和CIN组,两组之间具有显著性差异(P<0.05)。(2)在不同组织类型宫颈癌患者中,CA125、CA199、CYFRA21-1、SCC-Ag、CEA水平的差异具有统计学意义(P<0.05)。CA125、CA199、CEA在腺癌中的含量明显高于鳞癌、鳞腺癌(P<0.05),鳞癌与鳞腺癌的比较无统计学意义(P>0.05);CYFRA21-1、SCC-Ag在鳞癌中的含量明显高于腺癌、鳞腺癌(P<0.05),腺癌与鳞腺癌的比较无统计学意义(P>0.05)。结论:宫颈癌患者中的CA125、CA199、CYFRA21-1、SCC-Ag、CEA水平明显高于宫颈上皮内瘤变患者和健康者,SCC-Ag、CYFRA21-1在宫颈鳞癌患者中水平较高,CA125、CA199、CEA对宫颈腺癌的诊断更有意义,此五种肿瘤标志物可作为宫颈癌辅助诊断的检查指标,对鉴别宫颈癌病理分型同样具有一定的价值。